A recent study published in the British Journal of Ophthalmology has highlighted concerning findings regarding the weight-loss drug Wegovy, revealing that users face nearly five times the risk of sudden vision loss compared to those taking Ozempic, a diabetes medication. This alarming association raises critical questions about the safety profiles of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications, particularly their active ingredient, semaglutide.
Study Findings and Implications
The research, which analysed data from the US Food and Drug Administration’s adverse event reporting system between December 2017 and December 2024, indicated a stark contrast between the risks associated with Wegovy and Ozempic. Patients using Wegovy were found to be five times more susceptible to developing non-arteritic anterior ischemic optic neuropathy (Naion), a condition often referred to as an “eye stroke” due to its nature of abruptly diminishing blood flow to the optic nerve.
Interestingly, the study noted that men experienced a threefold increase in risk compared to women. The condition leads to sudden and typically irreversible vision loss, affecting approximately one in 10,000 users of semaglutide. Researchers caution that while the likelihood of Naion is low, the potential for a dose-dependent safety concern warrants attention.
The Mechanism Behind the Risk
Dr Edward Margolin, an ophthalmology expert from the University of Toronto and a co-author of the study, posits that the rapid weight loss associated with Wegovy may elevate the risk of developing Naion. He emphasised that the quick-acting nature and higher dosages of Wegovy compared to other semaglutide formulations, such as Ozempic and Rybelsus, could contribute to this increased risk. The research compared the adverse effects reported for a weekly injectable dose of up to 2mg of Ozempic, 2.4mg of Wegovy, and a daily Rybelsus tablet.
The study’s authors concluded that the heightened association with Wegovy could stem from its more concentrated formulation and faster absorption rate. In contrast, the slower uptake of Rybelsus tablets did not reveal a discernible link to Naion.
Regulatory Responses and Safety Measures
In light of these findings, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update in February, alerting healthcare providers and patients to the potential risk of Naion associated with semaglutide. Dr Alison Cave, the MHRA’s chief safety officer, reassured the public that while the risk remains exceedingly low, awareness of symptoms is crucial for timely intervention.
A spokesperson for Novo Nordisk, the manufacturer of Wegovy, Ozempic, and Rybelsus, stated that patient safety is paramount and affirmed their commitment to monitoring adverse events associated with their medications. They also highlighted that updated patient leaflets would include warnings about Naion, although they maintain that current evidence does not support a causal relationship between semaglutide and the condition.
Clinical Perspectives and Future Research
While the research presents significant findings, some experts urge caution in interpretation. Dr Samantha Mann, a consultant ophthalmologist and lead on diabetic eye screening at the Royal College of Ophthalmologists, noted that the study relies solely on reported side effects and cannot definitively establish causation or prevalence. She pointed out that an increase in Naion cases has not been prominently noted in clinical practice at St Thomas’ Hospital in London.
Given the implications for patient safety, further studies are essential to ascertain the true extent of this risk and to better understand the underlying mechanisms. The healthcare community must remain vigilant and proactive in monitoring these potential side effects associated with semaglutide and its derivatives.
Why it Matters
The linking of Wegovy to a heightened risk of sudden vision loss underscores the need for comprehensive safety evaluations of weight-loss medications. As obesity continues to be a significant public health challenge, understanding the benefits and risks of associated pharmacotherapies becomes paramount. This research serves as a reminder that while medications can provide substantial benefits, they may also carry hidden dangers that require careful consideration by both patients and healthcare providers. The ongoing dialogue surrounding patient safety and drug efficacy is crucial to ensuring informed decision-making in treatment options.
